Новини світу: у Данії засудили росіянина - Інформаційне агентство «Вголос» vgolos.com.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vgolos.com.ua Daily Mail and Mail on Sunday newspapers.
https://www.afinalwarning.com/511953.html (Natural News) There is a weak spot in the Earth’s magnetic field, and some scientists believe it may have been caused by the remnants of an ancient planet that impacted the Earth billions of years ago.
The Earth has a protective geomagnetic field that shields the planet from deadly solar radiation. This field is generated by a process that starts 2,000 miles below the surface of the planet, in the Earth’s outer core.
In the outer core, there is a gigantic mass of liquid iron swirling around. This generates the magnetic field that stretches from the outer core up to the space surrounding the Earth.
Semitransparent selenium solar cell for applications in tandem devices
The bifacial device showed a power conversion efficiency of 5.2% on the front side through an n-type contact and 2.7% on the rear side through a p-type contact.Scientists at the Technical University of Denmark have fabricated a bifacial selenium solar cell that can be used as a top-cell in tandem PV devices. Selenium (Se) is a suitable wide-bandgap absorber with a reported direct bandgap of 1.83-2 electronvolts for its crystallin trigonal allotrope, the researchers explained, adding that the semiconductor has low toxicity and the potential for a low-cost fabrication process. For the proposed .
Achilles Therapeutics PLC: Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
Research and Innovation program to develop a tool for the prediction of neoantigen immunogenicity
LONDON, May 06, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
Research and Innovation program to develop a tool for the prediction of neoantigen immunogenicity
LONDON, May 06, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.